|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | |  | | **Supplemental Table 2.** Patient diagnosis, courses received, best response | | | | | | |
| **PT ID#** | **Cell**  **Type** | | **Diagnosis** | | **Dose**  (mg/m2/d) | **Courses**  **#** | **Best Response** | **PFS**  (months) | **Status**  (+months) |
| 6 | T-cell | | NHL angioimmunoblastic | | 1810a | 6 | **PRu** | 6 |  |
| 5 | T-cell | | NHL cutaneous | | 1280a | 1 | n/e |  |  |
| 10 | T-cell | | NHL cutaneous /Sézary | | 1280a | 25 | **CR** | 68+ | CR +68c |
| 25 | T-cell | | NHL cutaneous | | 1280a | 7 | SD | 6 | Alive +83d |
| 26 | T-cell | | NHL cutaneous | | 600-1200b | 4 | SD |  |  |
| 28 | T-cell | | NHL Gamma/delta | | 600-1200b | 2 | SD |  |  |
| 13 | T-cell | | NHL cutaneous | | 905a | 3 | PD |  |  |
| 14 | T-cell | | NHL angioimmunoblastic | | 905a | 4 | **CRu** | 14+ | Alive +118e |
| 16 | T-cell | | NHL cutaneous | | 905a | <1 | n/e |  |  |
| 17 | T-cell | | NHL cutaneous /Sézary | | 905a | 6 | **PRu** | 5 |  |
| 18 | T-cell | | NHL cutaneous /Sézary | | 640a | 12 | SD | 8 |  |
| 19 | T-cell | | NHL peripheral, NOS | | 640a | 3 | PD |  |  |
| 20 | T-cell | | NHL angioimmunoblastic | | 640a | 2 | SD |  |  |
| 7 | B-cell | | CLL/SLL | | 1810 | <1 | PD |  |  |
| 9 | B-cell | | NHL marginal zone | | 1280 | <1 | PD |  |  |
| 11 | B-cell | | NHL diffuse large cell | | 1280 | 3 | SD |  |  |
| 12 | B-cell | | Hodgkin's disease (NS) | | 1280 | 1 | PD |  |  |
| 23 | B-cell | | Hairy cell leukemia | | 1280 | 2 | SD |  |  |
| 24 | B-cell | | CLL (NOS) | | 1280a | 2 | PD |  |  |
| 27 | B-cell | | NHL Mantle cell | | 600-1200b | 1 | PD |  |  |
| 15 | B-cell | | NHL follicular lymphoma | | 905 | 2 | PD |  |  |
| 4 | B-cell | | CLL / SLL | | 640 | 1 | PD |  |  |
| 3 | B-cell | | NHL diffuse large | | 320 | 2 | **PRu** |  |  |
| 2 | B-cell | | CLL/ SLL | | 160 | 1 | PD |  |  |
| 29 | mixed | | NHL mixed PTCL / large diffuse B-cell | | 600-1200b | 1 | PD |  |  |
| 8 |  | | AML-M1 | | 1810 | <1 | PD |  |  |
| 1 |  | | AML-M2 | | 80 | 2 | PD |  |  |
| 22 |  | | Multiple myeloma | | 905 | 1 | PD |  |  |
| 21 |  | | ALL pre-B (pre-transplant) | | 640 | 3 | n/e |  |  |
|  | |  | | a patient had dose reduction during protocol therapy  b modified reduced Day 1 dosing  c last contact – lost to follow-up  d residual disease, periodic treatment with other agents  e relapsed at +113 months with phenotypic drift to Follicular Helper T-cell  n/e = not evaluable  CRu = complete response, unconfirmed (lacking marrow response confirmation)  PRu = partial response, unconfirmed (lacking marrow response confirmation) | | | | | | |